hameln pharma ApS: Financial statements 2020
CVR: 39720213
Source: annual report 2020, Danish Business Authority
01/01/2020 – 31/12/2020
hameln pharma ApS (CVR 39720213) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 2,403,938 and a net result of DKK 1,863,764. Equity in the 2020 report amounted to DKK 1,831,033. The solvency ratio was 30.7%.
- Gross Profit
- DKK 2,403,938
- Profit/Loss
- DKK 1,863,764
- Equity
- DKK 1,831,033
- Total Assets
- DKK 5,960,152
- Employees
- 0
How creditworthy is hameln pharma ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Hameln pharma ApS has published its interim report for the period July 9, 2018 – December 31, 2019.
About hameln pharma ApS
hameln pharma ApS is a Danish company of the type Anpartsselskab based in Glostrup, founded in 2018. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The management consists of Frank Jahrand and Stephen Allen Watkin. The company is owned by hameln pharma gmbh. According to the 2025 annual report, the company had an average of 0 employees. In 2025, the company reported a gross profit of DKK 10,300,176 and a net result of DKK 8,050,599 compared with DKK 5,288,671 the year before. Equity in the 2025 report amounted to DKK 20,334,774.